[HTML][HTML] Graft-versus-myeloma effect: proof of principle

G Tricot, DH Vesole, S Jagannath, J Hilton, N Munshi… - Blood, 1996 - Elsevier
G Tricot, DH Vesole, S Jagannath, J Hilton, N Munshi, B Barlogie
Blood, 1996Elsevier
The presence of a graft-versus-tumor effect has been well established in leukemia but not in
multiple myeloma. A 40-year-old patient with myeloma refractory to standard chemotherapy
and autologous transplantation received a matched unrelated T-cell-depleted transplant
after conditioning with fractionated total-body irradiation, thiotepa, and cyclophosphamide.
This procedure resulted in a transient and incomplete response with evidence of rapidly
progressive disease within 2.5 months posttransplantation. The patient then received a …
The presence of a graft-versus-tumor effect has been well established in leukemia but not in multiple myeloma. A 40-year-old patient with myeloma refractory to standard chemotherapy and autologous transplantation received a matched unrelated T-cell-depleted transplant after conditioning with fractionated total-body irradiation, thiotepa, and cyclophosphamide. This procedure resulted in a transient and incomplete response with evidence of rapidly progressive disease within 2.5 months posttransplantation. The patient then received a small number of donor peripheral blood (PB) mononuclear cells (CD3 cells 1.2 × 106/kg) without any further cytotoxic therapy. A complete remission was attained, lasting now for more than 14 months. The procedure was associated with severe acute and subsequently limited chronic graft-versus-host disease (GVHD). This report provides the first direct evidence of a graft-versus-myeloma effect after allogeneic transplantation.
Elsevier